Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1993-05-18
1995-04-11
Rollins, John W.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
A61K 3170
Patent
active
054058376
ABSTRACT:
The present invention relates to the treatment of neoplastic disease in warm blooded animals using the sequential administration of tiazofurin and ribavirin. Tiazofurin is administered first in a high dose in order to facilitate a sharp decrease in IMP DH activity. These gains are consolidated by the continual administration of tiazofurin until the hematological levels have stabilized and remission is achieved. Once the patient is in remission, ribavirin is administered in steadily tapering dosages until the minimum dosage that will retain the beneficial effect of the tiazofurin is achieved. The IMP DH activity, GTP concentration, and hematological data is continually monitored throughout the treatment and dosages adjusted.
REFERENCES:
patent: 4211771 (1980-07-01), Witkowski
patent: 4680285 (1987-07-01), Robins
Zhen et al., Cancer Investigation, vol. 10, No. 6, pp. 505-511, (1992).
Look et al., Gynecologic Oncology, vol. 47, pp. 66-70, (1992).
Ban et al., Biochemical and Biophysical Research Communications, vol. 184, No. 2, pp. 551-559, (1992).
Weber et al., Cancer Research, vol. 53, pp. 5982-5986, (1993).
Jayaram et al., Cancer Chemotherapy and Pharmacology, pp. 93-96, (1992).
Jayaram et al., Int. J. Cancer, vol. 51, pp. 182-188, (1992).
Batist et al., Investigational New Drugs, vol. 3, pp. 349-355 (1985).
Roberts et al., Cancer Treatment Reports, vol. 71, No. 2, pp. 141-149, (1987).
Kovacs et al., J. Med. Chem, vol. 25, No. 1, pp. 107-108, (1982).
Taniki et al., Cancer Biochem. Biophys., vol. 13, pp. 295-302, (1993).
Tricot et al., Int. J. of Cell Cloning, vol. 8, pp. 161-170, (1990).
Tricot et al., Cancer Research, vol. 47, pp. 4988-4991, (1987).
Tricot et al., Cancer Research, vol. 49, pp. 3696-3701, (1989).
Weber et al., Cancer Communications, vol. 3, No. 3, pp. 61-66, (1991).
Weber et al., Advances in Enzyme Regulation, vol. 27, pp. 405-433, (1988).
Weber, Advances In Enzyme Regulation, vol. 29, pp. 75-95.
Yamada et al., Biochemistry, vol. 27, pp. 2193-2196, (1988).
Yamaji et al., Life Sciences, vol. 46, pp. 435-442, (1990).
Natsumeda et al., Biochemical And Biophysical Research Comm., vol. 153, No. 1, pp. 321-327, (1988).
Lui et al., The J. of Biol. Chem., vol. 259, No. 8, pp. 5078-5082, (1984).
Sidwell et al., Antiviral Research, vol. 1, pp. 47-53, (1981).
Natsumeda et al., Biochem and Biophys. Res. Commun., vol. 153, No. 1, pp. 321-327 (1988).
"The Conversion of 2-.beta.-D-Ribofuranosylthiazole-4-Carboxamide to an Analogue of NAD With Potent IMP Dehudrogenase-Inhibitory Properties" from Biochemical Pharmacology vol. 31, No. 11, pp. 2133-2135, 1982.
"Immunological Control of Virus-associated Tumors in Man: Prospects and Problems" Cancer Research, vol. 36, No. 2 CNREAB-pp. 559-869.
Article from Cancer Research and Clinical Oncology, vol. 98, No. 1, 1980.
Antiviral Research vol. 1, No. 1, Mar. 1981 regrding "Bovine Leukemia Virus Inhibition in Vitro by Ribavirin" Proceeding from the seventy-third annual meeting of the American Association for Cancer Reserch, Apr. 28-May 1, 1982.
Indiana University Foundation
Rollins John W.
Wilson James O.
LandOfFree
Method for the treatment of neoplastic disease utilizing tiazofu does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the treatment of neoplastic disease utilizing tiazofu, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the treatment of neoplastic disease utilizing tiazofu will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1538573